Ambulatory teclistamab administration in patients with relapsed/refractory multiple myeloma

被引:0
|
作者
Tabbara, Nadeem
Singel, Michael
Allen, Natalie
Mooney, Kathy
Shedeck, Audra
Zukas, Amber
Campion, Kate
Sollenberger, Callan
Gocke, Christian Burris
Ali, Syed Abbas
Huff, Carol Ann
Imus, Philip H.
Waheed, Sarah
机构
[1] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Washington, DC USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
11146
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Hindie, Elif
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (18): : 1721 - 1723
  • [2] Teclistamab in Relapsed or Refractory Multiple Myeloma
    Moreau, Philippe
    Garfall, Alfred L.
    van de Donk, Niels W. C. J.
    Nahi, Hareth
    San-Miguel, Jesus F.
    Oriol, Albert
    Nooka, Ajay K.
    Martin, Thomas
    Rosinol, Laura
    Chari, Ajai
    Karlin, Lionel
    Benboubker, Lotfi
    Mateos, Maria-Victoria
    Bahlis, Nizar
    Popat, Rakesh
    Besemer, Britta
    Martinez-Lopez, Joaquin
    Sidana, Surbhi
    Delforge, Michel
    Pei, Lixia
    Trancucci, Danielle
    Verona, Raluca
    Girgis, Suzette
    Lin, Shun X. W.
    Olyslager, Yunsi
    Jaffe, Mindy
    Uhlar, Clarissa
    Stephenson, Tara
    Van Rampelbergh, Rian
    Banerjee, Arnob
    Goldberg, Jenna D.
    Kobos, Rachel
    Krishnan, Amrita
    Usmani, Saad Z.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (06): : 495 - 505
  • [3] Teclistamab for relapsed refractory multiple myeloma patients on dialysis
    Lebreton, P.
    Lachenal, F.
    Bouillie, S.
    Pica, G. M.
    Aftisse, H.
    Pascal, L.
    Montes, L.
    Macro, M.
    Johnson, N.
    Harel, S.
    Fernandez, M.
    De Renzis, B.
    Lioure, B.
    Lazareth, A.
    Javelot, M.
    Louni, C.
    Huart, A.
    Perrot, A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (05) : 2077 - 2079
  • [4] Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
    Cohen, Yael C.
    Magen, Hila
    Gatt, Moshe
    Sebag, Michael
    Kim, Kihyun
    Min, Chang-Ki
    Ocio, Enrique M.
    Yoon, Sung-Soo
    Chu, Michael P.
    Rodriguez-Otero, Paula
    Avivi, Irit
    Quijano Carde, Natalia A.
    Kumar, Ashwini
    Krevvata, Maria
    Peterson, Michelle R.
    Di Scala, Lilla
    Scott, Emma
    Hilder, Brandi
    Vanak, Jill
    Banerjee, Arnob
    Oriol, Albert
    Morillo, Daniel
    Mateos, Maria-Victoria
    NEW ENGLAND JOURNAL OF MEDICINE, 2025, 392 (02): : 138 - 149
  • [5] Teclistamab in Relapsed Refractory Multiple Myeloma Patients on Dialysis: A French Experience
    Lachenal, Florence
    Lebreton, Pierre
    Bouillie, Sylvie
    Matteo, Gian
    Aftisse, Hassina
    Pascal, Laurent
    Montes, Lydia
    Macro, Margaret
    Vignon, Marguerite
    Harel, Stephanie
    Fernandez, Mariana
    Louni, Chanaz
    Huart, Antoine
    Perrot, Aurore
    BLOOD, 2023, 142
  • [6] Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria R.
    BLOOD CANCER JOURNAL, 2025, 15 (01):
  • [7] Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma
    Davis, James A.
    Snyder, Jordan
    Rice, Mikhaila
    Moore, Donald C.
    Cahoon, Christopher
    Julian, Kelley
    Wagner, Charlotte B.
    Granger, Katelynn
    Green, Kimberly M.
    Atrash, Shebli
    Hill, Hailey
    Mcelwee, Jessica
    Elsey, Grace
    Khouri, Jack
    Rudoni, Joslyn
    Mahmoudjafari, Zahra
    Nachar, Victoria
    BLOOD, 2024, 144 : 2382 - 2383
  • [8] Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma
    Girgis, Suzette
    Lin, Shun Xin Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi W.
    Russell, Jeffery
    Infante, Jeffrey
    Elsayed, Yusri
    Smit, Jennifer
    Goldberg, Jenna D.
    BLOOD ADVANCES, 2023, 7 (04) : 644 - 648
  • [9] Use of Baseline Inflammatory Markers to Predict Toxicities Among Relapsed/Refractory Multiple Myeloma Patients Receiving Ambulatory Teclistamab and Talquetamab
    Tabbara, Nadeem
    Singel, Michael
    Allen, Natalie
    Shedeck, Audra
    Mooney, Kathy
    Campion, Kathryn
    Raymond, Callan
    Sabirzhanova, Inna
    Anderson, Karen
    Waheed, Sarah
    Huff, Carol Ann
    Ali, Syed Abbas
    Gocke, Christian B.
    Imus, Philip
    BLOOD, 2024, 144 : 7232 - 7233
  • [10] Real World Evaluation of Teclistamab: A Focus on Infections in Patients With Relapsed Refractory Multiple Myeloma (RRMM)
    Asoori, Sireesha
    Martin, Thomas
    Wolf, Jeffrey
    Chung, Alfred
    Arora, Shagun
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S536 - S537